AURORA CANNABIS INC (ACB.CA) Stock Fundamental Analysis

TSX:ACB • CA05156X8504

4.87 CAD
+0.28 (+6.1%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

ACB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. ACB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ACB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ACB has reported negative net income.
  • ACB had a positive operating cash flow in the past year.
  • ACB had negative earnings in 4 of the past 5 years.
  • In the past 5 years ACB reported 4 times negative operating cash flow.
ACB.CA Yearly Net Income VS EBIT VS OCF VS FCFACB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1B -2B -3B

1.2 Ratios

  • ACB has a Return On Assets of -7.78%. This is comparable to the rest of the industry: ACB outperforms 54.55% of its industry peers.
  • With a decent Return On Equity value of -11.07%, ACB is doing good in the industry, outperforming 63.64% of the companies in the same industry.
Industry RankSector Rank
ROA -7.78%
ROE -11.07%
ROIC N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ACB.CA Yearly ROA, ROE, ROICACB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

  • With a Gross Margin value of 1.69%, ACB is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of ACB has declined.
  • The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
ACB.CA Yearly Profit, Operating, Gross MarginsACB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ACB has been increased compared to 1 year ago.
  • The number of shares outstanding for ACB has been reduced compared to 5 years ago.
  • ACB has a better debt/assets ratio than last year.
ACB.CA Yearly Shares OutstandingACB.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACB.CA Yearly Total Debt VS Total AssetsACB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • Based on the Altman-Z score of -10.71, we must say that ACB is in the distress zone and has some risk of bankruptcy.
  • ACB has a Altman-Z score of -10.71. This is amonst the worse of the industry: ACB underperforms 84.85% of its industry peers.
  • A Debt/Equity ratio of 0.07 indicates that ACB is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.07, ACB is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -10.71
ROIC/WACCN/A
WACC8.71%
ACB.CA Yearly LT Debt VS Equity VS FCFACB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • ACB has a Current Ratio of 3.41. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
  • ACB has a better Current ratio (3.41) than 84.85% of its industry peers.
  • A Quick Ratio of 1.63 indicates that ACB should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.63, ACB is doing good in the industry, outperforming 69.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.41
Quick Ratio 1.63
ACB.CA Yearly Current Assets VS Current LiabilitesACB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for ACB have decreased strongly by -502.65% in the last year.
  • ACB shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.32%.
  • The Revenue has been growing slightly by 6.94% on average over the past years.
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
Revenue 1Y (TTM)27.32%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%

3.2 Future

  • The Earnings Per Share is expected to grow by 103.58% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 1.81% on average over the next years.
EPS Next Y-1574.6%
EPS Next 2Y162.07%
EPS Next 3Y55.18%
EPS Next 5Y103.58%
Revenue Next Year11.1%
Revenue Next 2Y9.83%
Revenue Next 3Y9.81%
Revenue Next 5Y1.81%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ACB.CA Yearly Revenue VS EstimatesACB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ACB.CA Yearly EPS VS EstimatesACB.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 14.18, which indicates a correct valuation of ACB.
  • Based on the Price/Forward Earnings ratio, ACB is valued a bit cheaper than the industry average as 78.79% of the companies are valued more expensively.
  • ACB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 14.18
ACB.CA Price Earnings VS Forward Price EarningsACB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB.CA Per share dataACB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ACB's earnings are expected to grow with 55.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y162.07%
EPS Next 3Y55.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ACB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AURORA CANNABIS INC

TSX:ACB (2/13/2026, 7:00:00 PM)

4.87

+0.28 (+6.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)06-16
Inst Owners21.27%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap276.18M
Revenue(TTM)343.29M
Net Income(TTM)-58.89M
Analysts74
Price Target8.4 (72.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-402.09%
Min EPS beat(2)-587.94%
Max EPS beat(2)-216.23%
EPS beat(4)1
Avg EPS beat(4)815.79%
Min EPS beat(4)-587.94%
Max EPS beat(4)4494.06%
EPS beat(8)2
Avg EPS beat(8)364.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.81%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)2.46%
Revenue beat(4)3
Avg Revenue beat(4)4.08%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)13.79%
Revenue beat(8)6
Avg Revenue beat(8)4.16%
Revenue beat(12)8
Avg Revenue beat(12)3.93%
Revenue beat(16)9
Avg Revenue beat(16)2.81%
PT rev (1m)3.97%
PT rev (3m)3.97%
EPS NQ rev (1m)-37.5%
EPS NQ rev (3m)-27.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-682.17%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.18
P/S 0.75
P/FCF N/A
P/OCF 123.13
P/B 0.52
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)0.34
Fwd EY7.05%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)0.04
OCFY0.81%
SpS6.47
BVpS9.38
TBVpS8.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.78%
ROE -11.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.69%
FCFM N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.37%
Cap/Sales 5.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.41
Quick Ratio 1.63
Altman-Z -10.71
F-Score5
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
EPS Next Y-1574.6%
EPS Next 2Y162.07%
EPS Next 3Y55.18%
EPS Next 5Y103.58%
Revenue 1Y (TTM)27.32%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%
Revenue Next Year11.1%
Revenue Next 2Y9.83%
Revenue Next 3Y9.81%
Revenue Next 5Y1.81%
EBIT growth 1Y-6.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year122.51%
EBIT Next 3Y30.92%
EBIT Next 5Y21.79%
FCF growth 1Y87.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.77%
OCF growth 3YN/A
OCF growth 5YN/A

AURORA CANNABIS INC / ACB.CA FAQ

Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ACB.CA.


What is the valuation status of AURORA CANNABIS INC (ACB.CA) stock?

ChartMill assigns a valuation rating of 2 / 10 to AURORA CANNABIS INC (ACB.CA). This can be considered as Overvalued.


What is the profitability of ACB stock?

AURORA CANNABIS INC (ACB.CA) has a profitability rating of 1 / 10.